Prostaglandin periostitis

Prostaglandin periostitis

Show titles
Hide titles
Overview
Case 1 Prostaglandin periostitis
Case 2 Prostaglandin periostitis
Case 3 Prostaglandin periostitis
Case 4 Prostaglandin periostitis

Prostaglandin periostitis

Overview

Case 1
Prostaglandin periostitis
Case 2
Prostaglandin periostitis
Case 3
Prostaglandin periostitis
Case 4
Prostaglandin periostitis
History: 27-day-old female with a congenital heart defect (DORV, VSD)

Findings

Diffuse periosteal bone formation.

Differential
  • Prostaglandin periostitis
  • Physiologic periostitis
  • Trauma
  • Caffey's disease
  • Congenital syphilis
  • Hypervitaminosis A
  • Scurvy
  • Hypertrophic osteoarthropathy
  • Leukemia
  • Skeletal metastasis
Impression

Prostaglandin periostitis

Discussion
  • Prostaglandin E1 is commonly used to maintain a patent ductus arteriosus in patients with ductus-dependent congenital heart disease.
  • Periosteal bone formation is usually seen with long-term prostaglandin treatment (>40 days), but can be seen with short-term therapy with prostaglandin E2 (9-14 days).
  • Symmetrical distribution is not always present.
  • Generally self-limited with no effect on subsequent bone growth and development.
  • Complete resolution common in 6 months to 1 year.
History: 25 day old male with Tetralogy of Fallot

Findings
Diffuse periosteal bone reaction

Cardiomegaly and boot-shaped heart consistent with the provided history of Tetralogy of Fallot

Differential
  • Prostaglandin periostitis
  • Physiologic periostitis
  • Trauma
  • Caffey's disease
  • Congenital syphilis
  • Hypervitaminosis A
  • Scurvy
  • Hypertrophic osteoarthropathy
  • Leukemia
  • Skeletal metastasis
Impression

Prostaglandin periostitis

Discussion
  • Prostaglandin E1 is commonly used to maintain a patent ductus arteriosus in patients with ductus-dependent congenital heart disease (such as TOF in this case).
  • Periosteal bone formation is usually seen with long-term prostaglandin treatment (>40 days), but can be seen with short-term therapy with prostaglandin E2 (9-14 days).
  • Symmetrical distribution is not always present.
  • Generally self-limited with no effect on subsequent bone growth and development.
  • Complete resolution common in 6 months to 1 year.
History: 3-month-old female with a ventricular septal defect

Findings
Periosteal reaction involving the left humerus, scapula, and ulna.
Differential
  • Prostaglandin periostitis
  • Physiologic periostitis
  • Trauma
  • Caffey's disease
  • Congenital syphilis
  • Hypervitaminosis A
  • Scurvy
  • Hypertrophic osteoarthropathy
  • Leukemia
  • Skeletal metastasis
Impression

Prostaglandin periostitis

Discussion
  • Prostaglandin E1 is commonly used to maintain a patent ductus arteriosus in patients with ductus-dependent congenital heart disease.
  • Periosteal bone formation is usually seen with long-term prostaglandin treatment (>40 days), but can be seen with short-term therapy with prostaglandin E2 (9-14 days).
  • Symmetrical distribution is not always present (as in this case)
  • Generally self-limited with no effect on subsequent bone growth and development.
  • Complete resolution common in 6 months to 1 year.
History: 2 month old male with Tetralogy of Fallot

Findings
Diffuse periosteal bone formation involving the femur, tibia, and fibula
Differential
  • Prostaglandin periostitis
  • Physiologic periostitis
  • Trauma
  • Caffey's disease
  • Congenital syphilis
  • Hypervitaminosis A
  • Scurvy
  • Hypertrophic osteoarthropathy
  • Leukemia
  • Skeletal metastasis
Impression

Prostaglandin periostitis

Discussion
  • Prostaglandin E1 is commonly used to maintain a patent ductus arteriosus in patients with ductus-dependent congenital heart disease (such as TOF in this case)
  • Periosteal bone formation is usually seen with long-term prostaglandin treatment (>40 days), but can be seen with short-term therapy with prostaglandin E2 (9-14 days)
  • Symmetrical distribution is not always present.
  • Generally self-limited with no effect on subsequent bone growth and development.
  • Complete resolution common in 6 months to 1 year